Orthomyxoviridae Infections is an indication for drug development with over 470 pipeline drugs currently active. According to GlobalData, preregistered drugs for Orthomyxoviridae Infections have a 93.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Orthomyxoviridae Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orthomyxoviridae Infections overview
The family Orthomyxoviridae is defined by viruses that have a negative-sense, single-stranded, and segmented RNA genome. The orthomyxoviridae family, containing influenza -A, – B and -C viruses, are enveloped RNA viruses that cause upper respiratory tract infections characterized by fever, chills, headache, generalized muscular aching, and loss of appetite . Research of Orthomyxoviridae Infections has been linked to Influenza, Virus Diseases, Infective Disorder, Influenza In Birds, Influenza Due To Influenza A Virus Subtype H1n1. Pathways related to Orthomyxoviridae Infections include Immune Response, Pathogenesis, Virulence, Viral Replication, Inflammatory Response. These pathways complement our catalog of research reagents for the study of Orthomyxoviridae Infections including antibodies and ELISA kits against PRH2, TMEM37, PGR, TNF, CD8A.
For a complete picture of PTSR and LoA scores for drugs in Orthomyxoviridae Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
